A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Di Nicola Massimo
Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)
Drug: BMS-986482, Nivolumab, Relatlimab, Bevacizumab
Pathologies: Advanced Solid Tumours, Melanoma, Pancreatic cancer, Lung cancer, Breast cancer, Intestinal cancer, Head and neck cancers, Stomach tumors, Urological cancers (kidney, bladder, urinary tract, others)
ClinicalTrials.gov: Read the details about clinical trials
This protocol is an open-label, multi-center, first-in-human (FIH) phase 1/2 study testing the safety and efficacy of BMS-986482 alone and in combination with nivolumab, with nivolumab and relatlimab, or in combination with bevacizumab in advanced solid tumors.
BMS-986482 is an orally administered, Ikaros-family zinc finger pan-degrader (IKZF-PD) with deep HELIOS+EOS and moderate IKAROS+AIOLOS degradation activity. It is designed to induce regulatory T (Treg) cell reprogramming and activation of effector T cells to boost antitumor immunity and improve outcomes in solid tumor indications.
Last update: 21/04/2026